Don’t let the cost of severe asthma treatment limit your breathing. We help eligible
patients access Fasenra (benralizumab) for as little as $69.95 per month through
manufacturer Patient Assistance Programs.
The Fasenra Prescription Assistance Program is a manufacturer-sponsored initiative that provides Fasenra at no medication cost to qualifying patients who cannot afford it. The program is designed for uninsured and underinsured patients, Medicare Part D patients, and commercially insured patients whose coverage has been denied. If approved, you receive your Fasenra injections free of charge, with enrollment for up to 12 months at a time.
Navigating this program on your own, however, means dealing with eligibility requirements, prescriber coordination, specialty pharmacy logistics, and annual re-enrollment deadlines — all while managing severe asthma that demands uninterrupted treatment.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing injections and annual re- enrollment, so you never face a gap in your biologic therapy.
Medicare Part D patients accepted. If you have Medicare Part D coverage, you may still qualify forthe Patient Assistance Program through case-by-case exceptions.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$5,250.00 | Save ~$5180.05/mo |
| CVS Pharmacy | ~$5,200.00 | Save ~$5130.05/mo |
| Walmart | ~$5,200.00 | Save ~$5130.05/mo |
| Costco | ~$5,200.00 | Save ~$5130.05/mo |
| Kroger | ~$5,197.33 | Save ~$5127.38/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management. Our $69.95/month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long-term solution:
Eligibility is generally determined by annual household income levels. Most programs follow guidelines that include a limit of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because these requirements can vary, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for assistance.
Fasenra (benralizumab) is a prescription self-injectable biologic for severe eosinophilic asthma in patients age 6 and older, and for adults with eosinophilic granulomatosis with polyangiitis (EGPA). It is administered as a subcutaneous injection (30 mg) every 4 weeks for the first 3 doses, then every 8 weeks thereafter for severe asthma — meaning approximately 6–7 injections per year. Fasenra is not a rescue medication and is not used for sudden breathing problems.
How It Works:
In severe eosinophilic asthma, your immune system produces too many eosinophils — white blood cells that drive chronic airway inflammation, tissue damage, and severe attacks. These cells accumulate in your lung tissue, making your airways hyperreactive.
Fasenra targets a protein called the interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils. Unlike other biologics that simply block the signal to produce eosinophils, Fasenra goes further — it flags eosinophils for destruction by your own immune system through a process called antibody- dependent cell-mediated cytotoxicity (ADCC). This results in near-complete depletion of eosinophils from your blood and airways, dramatically reducing inflammation. You self-inject Fasenra using a prefilled autoinjector or syringe into the thigh, abdomen, or upper arm.
Form and Use:
Available as a 30 mg/mL prefilled autoinjector pen or syringe. For severe eosinophilic asthma: one injection every 4 weeks for the first 3 doses, then one injection every 8 weeks. For EGPA: one injection every 4 weeks.
Generic Availability:
As of April 2026, no generic or biosimilar version of Fasenra (benralizumab) is available in the United States. As a biologic, the equivalent would be a biosimilar rather than a traditional generic — and no biosimilar has received FDA approval. Development timelines remain uncertain.
Warnings:
Fasenra is not a rescue medication — do not use it to treat sudden breathing problems. Do not stop taking corticosteroids unless instructed by your healthcare provider. Allergic reactions, including anaphylaxis, can occur. Stopping Fasenra without medical supervision can allow eosinophils to return and severe asthma to worsen.
Fasenra costs approximately $5,197–$6,022 per injection, totaling $39,000–$45,000 per year at maintenance dosing. Through AffordMyPrescriptions, qualifying patients receive Fasenra at no medication cost — our $69.95 monthly fee covers advocacy and program management.
Yes. Fasenra obtained through the Patient Assistance Program is the same FDA-approved 30 mg/mL prefilled autoinjector or syringe, manufactured by the same company, that you would receive at any specialty pharmacy. It is shipped directly from the manufacturer’s program.
No. As of April 2026, no generic or biosimilar version of Fasenra is available in the United States. Until a biosimilar becomes available, the Patient Assistance Program is the most affordable access pathway.
Yes. The manufacturer’s PAP accepts Medicare Part D patients who meet income and eligibility criteria. We help you navigate the application process to access Fasenra at no medication cost.
Our Patient Advocates immediately explore every alternative — including the manufacturer’s $0 copay savings program for commercially insured patients, the denied-coverage program (up to 24 months free for insured patients denied coverage), independent co-pay foundations, insurance prior authorization appeals, and alternative biologics like Nucala or Dupixent through their own PAPs.
Approval typically takes 1–4 weeks depending on the program and your documentation. Our advocates expedite the process by preparing complete applications, coordinating with your pulmonologist, and proactively following up on your case.
If you are struggling with the high cost of Fasenra, our team may be able to help you
access assistance programs designed to make medications more affordable. Check
your eligibility today and take the first step toward reducing your prescription costs.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.